EDITAS MEDICINE, INC. Increase (Decrease) in Accrued Liabilities
EDITAS MEDICINE, INC. (EDIT) reported Increase (Decrease) in Accrued Liabilities of -$15.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-05
- EDITAS MEDICINE, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$4.04M, a 798.10% decline year-over-year.
- EDITAS MEDICINE, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$11.36M, a 771.12% decline year-over-year.
- EDITAS MEDICINE, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$14.91M, a 186.97% decline year-over-year.
- EDITAS MEDICINE, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$543.00K, a 153.50% decline year-over-year.
- EDITAS MEDICINE, INC. increase (decrease) in accrued liabilities for fiscal 2025 was -$13.18M, a 213.43% decline from fiscal 2024.
- EDITAS MEDICINE, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $11.62M, a 182.52% increase from fiscal 2023.
- EDITAS MEDICINE, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $4.11M, a 60.84% decline from fiscal 2022.
- EDITAS MEDICINE, INC. increase (decrease) in accrued liabilities for fiscal 2022 was $10.51M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$15.40M 10-Q · filed 2026-08-05 | -$30.31M derived: sum of 3 quarters · filed 2026-08-05 | -$30.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$11.36M 10-Q · filed 2026-05-05 | -$26.27M derived: sum of 2 quarters · filed 2026-05-05 | -$26.82M derived: sum of 3 quarters · filed 2026-05-05 | -$26.24M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$14.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$15.46M derived: sum of 2 quarters · filed 2026-03-09 | -$14.88M derived: sum of 3 quarters · filed 2026-08-05 | -$13.18M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$543.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $35.00K derived: sum of 2 quarters · filed 2026-08-05 | $1.73M 10-Q · filed 2025-11-10 | $18.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $578.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.27M 10-Q · filed 2026-08-05 | $19.42M derived: sum of 3 quarters · filed 2026-08-05 | $20.43M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.69M 10-Q · filed 2026-05-05 | $18.84M derived: sum of 2 quarters · filed 2026-05-05 | $19.85M derived: sum of 3 quarters · filed 2026-05-05 | $16.01M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $17.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $18.16M derived: sum of 2 quarters · filed 2026-03-09 | $14.32M derived: sum of 3 quarters · filed 2026-03-09 | $11.62M 10-K · filed 2026-03-09 |
| 2024-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$2.83M derived: sum of 2 quarters · filed 2025-11-10 | -$5.52M 10-Q · filed 2025-11-10 | -$1.43M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$3.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$6.54M 10-Q · filed 2025-08-12 | -$2.45M derived: sum of 3 quarters · filed 2025-08-12 | -$64.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$2.69M 10-Q · filed 2025-05-12 | $1.40M derived: sum of 2 quarters · filed 2025-05-12 | $3.78M derived: sum of 3 quarters · filed 2025-05-12 | -$7.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $4.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $6.47M derived: sum of 2 quarters · filed 2025-03-05 | $2.69M derived: sum of 3 quarters · filed 2025-03-05 | $4.11M 10-K · filed 2025-03-05 |
| 2023-09-30 | $2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$1.41M derived: sum of 2 quarters · filed 2024-11-04 | $22.00K 10-Q · filed 2024-11-04 | $11.01M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | -$3.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$2.36M 10-Q · filed 2024-08-07 | $8.63M derived: sum of 3 quarters · filed 2025-03-05 | $7.74M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | $1.43M 10-Q · filed 2024-05-08 | $12.42M derived: sum of 2 quarters · filed 2025-03-05 | $11.53M derived: sum of 3 quarters · filed 2025-03-05 | $15.91M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $10.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $10.10M derived: sum of 2 quarters · filed 2025-03-05 | $14.49M derived: sum of 3 quarters · filed 2025-03-05 | $10.51M 10-K · filed 2025-03-05 |
| 2022-09-30 | -$887.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $3.50M derived: sum of 2 quarters · filed 2023-11-03 | -$485.00K 10-Q · filed 2023-11-03 | $4.79M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $4.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $402.00K 10-Q · filed 2023-08-02 | $5.67M derived: sum of 3 quarters · filed 2024-02-28 | $2.25M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$3.98M 10-Q · filed 2023-05-05 | $1.29M derived: sum of 2 quarters · filed 2024-02-28 | -$2.13M derived: sum of 3 quarters · filed 2024-02-28 | $1.42M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $5.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.85M derived: sum of 2 quarters · filed 2024-02-28 | $5.40M derived: sum of 3 quarters · filed 2024-02-28 | -$4.17M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$3.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $124.00K derived: sum of 2 quarters · filed 2022-11-02 | -$9.44M 10-Q · filed 2022-11-02 | -$5.34M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $3.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$6.02M 10-Q · filed 2022-08-03 | -$1.92M derived: sum of 3 quarters · filed 2023-02-22 | $8.13M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | -$9.56M 10-Q · filed 2022-05-04 | -$5.46M derived: sum of 2 quarters · filed 2023-02-22 | $4.58M derived: sum of 3 quarters · filed 2023-02-22 | $5.79M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $14.15M derived: sum of 2 quarters · filed 2023-02-22 | $15.35M derived: sum of 3 quarters · filed 2023-02-22 | $1.71M 10-K · filed 2023-02-22 |
| 2020-09-30 | $10.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $11.25M derived: sum of 2 quarters · filed 2021-11-09 | -$2.39M 10-Q · filed 2021-11-09 | $11.59M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$12.44M 10-Q · filed 2021-08-05 | $1.54M derived: sum of 3 quarters · filed 2022-02-24 | $1.67M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$13.64M 10-Q · filed 2021-05-06 | $332.00K derived: sum of 2 quarters · filed 2022-02-24 | $468.00K derived: sum of 3 quarters · filed 2022-02-24 | $2.76M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $13.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $14.11M derived: sum of 2 quarters · filed 2022-02-24 | $16.41M derived: sum of 3 quarters · filed 2022-02-24 | $9.48M 10-K · filed 2022-02-24 |
| 2019-09-30 | $136.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $2.43M derived: sum of 2 quarters · filed 2020-11-06 | -$4.49M 10-Q · filed 2020-11-06 | -$2.79M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $2.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$4.63M 10-Q · filed 2020-08-07 | -$2.93M derived: sum of 3 quarters · filed 2021-02-26 | -$2.62M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$6.92M 10-Q · filed 2020-05-08 | -$5.22M derived: sum of 2 quarters · filed 2021-02-26 | -$4.91M derived: sum of 3 quarters · filed 2021-02-26 | -$1.63M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $2.01M derived: sum of 2 quarters · filed 2021-02-26 | $5.29M derived: sum of 3 quarters · filed 2021-02-26 | $4.04M 10-K · filed 2021-02-26 |
| 2018-09-30 | $312.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $3.60M derived: sum of 2 quarters · filed 2019-11-12 | $2.34M 10-Q · filed 2019-11-12 | $2.97M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $3.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $2.03M 10-Q · filed 2019-08-07 | $2.66M derived: sum of 3 quarters · filed 2020-02-26 | -$102.00K derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | -$1.25M 10-Q · filed 2019-05-08 | -$624.00K derived: sum of 2 quarters · filed 2020-02-26 | -$3.39M derived: sum of 3 quarters · filed 2020-02-26 | $953.00K derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $628.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$2.13M derived: sum of 2 quarters · filed 2020-02-26 | $2.21M derived: sum of 3 quarters · filed 2020-02-26 | -$8.33M 10-K · filed 2020-02-26 |
| 2017-09-30 | -$2.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.58M derived: sum of 2 quarters · filed 2018-11-08 | -$8.96M 10-Q · filed 2018-11-08 | -$1.16M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $4.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$6.20M 10-Q · filed 2018-08-07 | $1.61M derived: sum of 3 quarters · filed 2019-03-01 | $3.51M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | -$10.54M 10-Q · filed 2018-05-04 | -$2.73M derived: sum of 2 quarters · filed 2019-03-01 | -$832.00K derived: sum of 3 quarters · filed 2019-03-01 | -$512.00K derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $7.81M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $9.71M derived: sum of 2 quarters · filed 2019-03-01 | $10.03M derived: sum of 3 quarters · filed 2019-03-01 | $11.84M 10-K · filed 2019-03-01 |
| 2016-09-30 | $1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $2.22M derived: sum of 2 quarters · filed 2017-11-08 | $4.03M 10-Q · filed 2017-11-08 | $6.74M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $320.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $2.13M 10-Q · filed 2017-08-09 | $4.84M derived: sum of 3 quarters · filed 2018-03-08 | $5.38M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $1.81M 10-Q · filed 2017-05-15 | $4.52M derived: sum of 2 quarters · filed 2018-03-08 | $5.06M derived: sum of 3 quarters · filed 2018-03-08 | $4.48M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $3.24M derived: sum of 2 quarters · filed 2018-03-08 | $2.66M derived: sum of 3 quarters · filed 2018-03-08 | $3.53M 10-K · filed 2018-03-08 |
| 2015-09-30 | $540.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$40.00K derived: sum of 2 quarters · filed 2016-11-09 | $823.00K 10-Q · filed 2016-11-09 | |
| 2015-06-30 | -$580.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $283.00K 10-Q · filed 2016-08-10 | ||
| 2015-03-31 | $863.00K 10-Q · filed 2016-05-13 | |||
| 2014-12-31 | $861.00K 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |